Cargando…
Neutropenia and Infection Prophylaxis in Childhood Cancer
PURPOSE OF REVIEW: Pediatric oncology patients frequently experience episodes of prolonged neutropenia which puts them at high risk for infection with significant morbidity and mortality. Here, we review the data on infection prophylaxis with a focus on both pharmacologic and ancillary interventions...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885776/ https://www.ncbi.nlm.nih.gov/pubmed/35230594 http://dx.doi.org/10.1007/s11912-022-01192-5 |
_version_ | 1784660514911027200 |
---|---|
author | Villeneuve, Stephanie Aftandilian, Catherine |
author_facet | Villeneuve, Stephanie Aftandilian, Catherine |
author_sort | Villeneuve, Stephanie |
collection | PubMed |
description | PURPOSE OF REVIEW: Pediatric oncology patients frequently experience episodes of prolonged neutropenia which puts them at high risk for infection with significant morbidity and mortality. Here, we review the data on infection prophylaxis with a focus on both pharmacologic and ancillary interventions. This review does not include patients receiving hematopoietic stem cell transplantation. RECENT FINDINGS: Patients with hematologic malignancies are at highest risk for infection. Bacterial and fungal prophylaxis decrease the risk of infection in certain high-risk groups. Ancillary measures such as ethanol locks, chlorhexidine gluconate baths, GCSF, IVIG, and mandatory hospitalization do not have enough data to support routine use. There is limited data on risk of infection and role of prophylaxis in patients receiving immunotherapy and patients with solid tumors. Patients with Down syndrome and adolescent and young adult patients may benefit from additional supportive care measures and protocol modifications. SUMMARY: Consider utilizing bacterial and fungal prophylaxis in patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. More research is needed to evaluate other supportive care measures and the role of prophylaxis in patients receiving immunotherapy. |
format | Online Article Text |
id | pubmed-8885776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-88857762022-03-01 Neutropenia and Infection Prophylaxis in Childhood Cancer Villeneuve, Stephanie Aftandilian, Catherine Curr Oncol Rep Pediatric Oncology (KL Davis, Section Editor) PURPOSE OF REVIEW: Pediatric oncology patients frequently experience episodes of prolonged neutropenia which puts them at high risk for infection with significant morbidity and mortality. Here, we review the data on infection prophylaxis with a focus on both pharmacologic and ancillary interventions. This review does not include patients receiving hematopoietic stem cell transplantation. RECENT FINDINGS: Patients with hematologic malignancies are at highest risk for infection. Bacterial and fungal prophylaxis decrease the risk of infection in certain high-risk groups. Ancillary measures such as ethanol locks, chlorhexidine gluconate baths, GCSF, IVIG, and mandatory hospitalization do not have enough data to support routine use. There is limited data on risk of infection and role of prophylaxis in patients receiving immunotherapy and patients with solid tumors. Patients with Down syndrome and adolescent and young adult patients may benefit from additional supportive care measures and protocol modifications. SUMMARY: Consider utilizing bacterial and fungal prophylaxis in patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. More research is needed to evaluate other supportive care measures and the role of prophylaxis in patients receiving immunotherapy. Springer US 2022-03-01 2022 /pmc/articles/PMC8885776/ /pubmed/35230594 http://dx.doi.org/10.1007/s11912-022-01192-5 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Pediatric Oncology (KL Davis, Section Editor) Villeneuve, Stephanie Aftandilian, Catherine Neutropenia and Infection Prophylaxis in Childhood Cancer |
title | Neutropenia and Infection Prophylaxis in Childhood Cancer |
title_full | Neutropenia and Infection Prophylaxis in Childhood Cancer |
title_fullStr | Neutropenia and Infection Prophylaxis in Childhood Cancer |
title_full_unstemmed | Neutropenia and Infection Prophylaxis in Childhood Cancer |
title_short | Neutropenia and Infection Prophylaxis in Childhood Cancer |
title_sort | neutropenia and infection prophylaxis in childhood cancer |
topic | Pediatric Oncology (KL Davis, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885776/ https://www.ncbi.nlm.nih.gov/pubmed/35230594 http://dx.doi.org/10.1007/s11912-022-01192-5 |
work_keys_str_mv | AT villeneuvestephanie neutropeniaandinfectionprophylaxisinchildhoodcancer AT aftandiliancatherine neutropeniaandinfectionprophylaxisinchildhoodcancer |